The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
Yves Boucher - One of the best experts on this subject based on the ideXlab platform.
-
Taste Disorder s management a systematic review
Clinical Oral Investigations, 2020Co-Authors: Adeline Braud, Yves BoucherAbstract:BACKGROUND: Taste Disorder is a frequent drug-induced or disease-related oral trouble. Various pharmacological, surgical, or physical treatments have previously been proposed for Taste function recovery. OBJECTIVES: The aim of the present systematic review was to assess the effects of palliative and curative interventions on Taste recovery in light of recent literature. MATERIALS AND METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a search of the literature published up to June 2019 was conducted using MEDLINE via PubMed, EMBASE, and The US National Institutes of Health Trials Register (PROSPERO registration reference: CRD 42019139315). The methodological quality of the included trials was rated with the "Delphi list For Quality Assessment of Randomized Clinical Trials" and the Newcastle-Ottawa scale. RESULTS: From the 1842 titles first identified, 28 articles met the inclusion criteria. Interventions included zinc (aspartate, sulfate, gluconate, acetate, picolinate, and Polaprezinc®), esomeprazole, L-thyroxin, bethanechol, oral glutamine, delta-9-tetrahydrocannabinol, alpha-lipoic acid, Ginkgo biloba, artificial saliva, pilocarpine, local anesthesia, and improved oral hygiene. The quality of evidence ranged from poor to high. CONCLUSION: Improving oral hygiene may promote Taste ability. Zinc may prevent and alleviate Taste Disorder in patients undergoing head and neck radiotherapy. CLINICAL RELEVANCE: The systematic review provided evidence about the clinical efficacy of oral procedures, zinc supplementation, and palliative cares in dysgeusic patients. Further research is needed to find effective treatments with low adverse effects.
-
Taste Disorder’s management: a systematic review
Clinical Oral Investigations, 2020Co-Authors: Adeline Braud, Yves BoucherAbstract:Background Taste Disorder is a frequent drug-induced or disease-related oral trouble. Various pharmacological, surgical, or physical treatments have previously been proposed for Taste function recovery. Objectives The aim of the present systematic review was to assess the effects of palliative and curative interventions on Taste recovery in light of recent literature. Materials and methods In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a search of the literature published up to June 2019 was conducted using MEDLINE via PubMed, EMBASE, and The US National Institutes of Health Trials Register (PROSPERO registration reference: CRD 42019139315). The methodological quality of the included trials was rated with the “Delphi list For Quality Assessment of Randomized Clinical Trials” and the Newcastle-Ottawa scale. Results From the 1842 titles first identified, 28 articles met the inclusion criteria. Interventions included zinc (aspartate, sulfate, gluconate, acetate, picolinate, and Polaprezinc®), esomeprazole, l -thyroxin, bethanechol, oral glutamine, delta-9-tetrahydrocannabinol, alpha-lipoic acid, Ginkgo biloba , artificial saliva, pilocarpine, local anesthesia, and improved oral hygiene. The quality of evidence ranged from poor to high. Conclusion Improving oral hygiene may promote Taste ability. Zinc may prevent and alleviate Taste Disorder in patients undergoing head and neck radiotherapy. Clinical relevance The systematic review provided evidence about the clinical efficacy of oral procedures, zinc supplementation, and palliative cares in dysgeusic patients. Further research is needed to find effective treatments with low adverse effects.
Yoshiki Sekijima - One of the best experts on this subject based on the ideXlab platform.
-
Taste Disorder in facial onset sensory and motor neuronopathy: a case report
BMC Neurology, 2020Co-Authors: Nobuhiko Ohashi, Jin Nonami, Minori Kodaira, Kunihiro Yoshida, Yoshiki SekijimaAbstract:Background Taste Disorder is a common symptom in the general population. Several studies have shown that patients with neurological Disorders, such as amyotrophic lateral sclerosis and Parkinson’s disease, develop Taste disturbance. Facial onset sensory and motor neuronopathy (FOSMN) is a rare disease characterized by sensory disturbance and weakness spreading from the face to the limbs caudally. We describe a patient with FOSMN who showed Taste Disorder as the sole initial symptom. Case presentation A 49-year-old man who smoked cigarettes developed Taste disturbance. Despite using zinc supplements, an herbal medication, and an ointment, his Taste Disorder worsened. 4 years later, a tingling feeling emerged at the tip of his tongue and gradually spread to his entire lips. At 55 years of age, he showed difficulty in swallowing, followed by facial paresthesia, muscle atrophy, and weakness in the face and upper limbs without apparent upper motor neuron sign. Cessation of smoking did not improve his Taste disturbance, and he was unable to discriminate different Tastes on the entire tongue. In an electrogustometric study, electrical stimulation did not induce any type of Taste sensation. Blink reflex showed delayed or diminished R2 responses. Needle electromyography revealed severe chronic neurogenic changes in the tongue and masseter muscles. Mild chronic neurogenic changes were also observed in the limbs. In the thoracic paraspinal muscles, active neurogenic changes were detected. Findings of hematological and cerebrospinal fluid analyses, and magnetic resonance images of the brain and spinal cord were unremarkable. One cycle of intravenous immunoglobulin therapy did not improve his symptoms. We diagnosed him as having FOSMN with the sole initial symptom of Taste Disorder. Nine years after the onset of Taste Disorder, he developed impaired sensation of touch in the right upper limb and required tube feeding and ventilator support. Conclusion Taste Disorder can be the initial manifestation of FOSMN and might involve the solitary nucleus.
-
Taste Disorder in facial onset sensory and motor neuronopathy a case report
BMC Neurology, 2020Co-Authors: Nobuhiko Ohashi, Jin Nonami, Minori Kodaira, Kunihiro Yoshida, Yoshiki SekijimaAbstract:Taste Disorder is a common symptom in the general population. Several studies have shown that patients with neurological Disorders, such as amyotrophic lateral sclerosis and Parkinson’s disease, develop Taste disturbance. Facial onset sensory and motor neuronopathy (FOSMN) is a rare disease characterized by sensory disturbance and weakness spreading from the face to the limbs caudally. We describe a patient with FOSMN who showed Taste Disorder as the sole initial symptom. A 49-year-old man who smoked cigarettes developed Taste disturbance. Despite using zinc supplements, an herbal medication, and an ointment, his Taste Disorder worsened. 4 years later, a tingling feeling emerged at the tip of his tongue and gradually spread to his entire lips. At 55 years of age, he showed difficulty in swallowing, followed by facial paresthesia, muscle atrophy, and weakness in the face and upper limbs without apparent upper motor neuron sign. Cessation of smoking did not improve his Taste disturbance, and he was unable to discriminate different Tastes on the entire tongue. In an electrogustometric study, electrical stimulation did not induce any type of Taste sensation. Blink reflex showed delayed or diminished R2 responses. Needle electromyography revealed severe chronic neurogenic changes in the tongue and masseter muscles. Mild chronic neurogenic changes were also observed in the limbs. In the thoracic paraspinal muscles, active neurogenic changes were detected. Findings of hematological and cerebrospinal fluid analyses, and magnetic resonance images of the brain and spinal cord were unremarkable. One cycle of intravenous immunoglobulin therapy did not improve his symptoms. We diagnosed him as having FOSMN with the sole initial symptom of Taste Disorder. Nine years after the onset of Taste Disorder, he developed impaired sensation of touch in the right upper limb and required tube feeding and ventilator support. Taste Disorder can be the initial manifestation of FOSMN and might involve the solitary nucleus.
Matteo Bassetti - One of the best experts on this subject based on the ideXlab platform.
-
high prevalence of olfactory and Taste Disorder during sars cov 2 infection in outpatients
Journal of Medical Virology, 2020Co-Authors: Andrea De Maria, Paola Varese, Chiara Dentone, Emanuela Barisione, Matteo BassettiAbstract:: Prevalent symptoms of SARS-CoV-2 in reports and metaanalyses refer to cough, fatigue, myalgia and respiratory distress. These represent clinically acknowledged relevant findings of valuable importance, particularly with the requirement for ventilation and hospital bed occupancy in ICUs. There is however a wide discordance with the actual picture of clinical presentation and symptoms in Italy. Here we comment on Sun and coll Metaanlysis with particular nuance to olfactory and Taste Disorders that very often herald SARS-CoV-2 in our country, particularly in outpatients, and are not reported so far in the medical literature from China. This article is protected by copyright. All rights reserved.
Adeline Braud - One of the best experts on this subject based on the ideXlab platform.
-
Taste Disorder s management a systematic review
Clinical Oral Investigations, 2020Co-Authors: Adeline Braud, Yves BoucherAbstract:BACKGROUND: Taste Disorder is a frequent drug-induced or disease-related oral trouble. Various pharmacological, surgical, or physical treatments have previously been proposed for Taste function recovery. OBJECTIVES: The aim of the present systematic review was to assess the effects of palliative and curative interventions on Taste recovery in light of recent literature. MATERIALS AND METHODS: In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a search of the literature published up to June 2019 was conducted using MEDLINE via PubMed, EMBASE, and The US National Institutes of Health Trials Register (PROSPERO registration reference: CRD 42019139315). The methodological quality of the included trials was rated with the "Delphi list For Quality Assessment of Randomized Clinical Trials" and the Newcastle-Ottawa scale. RESULTS: From the 1842 titles first identified, 28 articles met the inclusion criteria. Interventions included zinc (aspartate, sulfate, gluconate, acetate, picolinate, and Polaprezinc®), esomeprazole, L-thyroxin, bethanechol, oral glutamine, delta-9-tetrahydrocannabinol, alpha-lipoic acid, Ginkgo biloba, artificial saliva, pilocarpine, local anesthesia, and improved oral hygiene. The quality of evidence ranged from poor to high. CONCLUSION: Improving oral hygiene may promote Taste ability. Zinc may prevent and alleviate Taste Disorder in patients undergoing head and neck radiotherapy. CLINICAL RELEVANCE: The systematic review provided evidence about the clinical efficacy of oral procedures, zinc supplementation, and palliative cares in dysgeusic patients. Further research is needed to find effective treatments with low adverse effects.
-
Taste Disorder’s management: a systematic review
Clinical Oral Investigations, 2020Co-Authors: Adeline Braud, Yves BoucherAbstract:Background Taste Disorder is a frequent drug-induced or disease-related oral trouble. Various pharmacological, surgical, or physical treatments have previously been proposed for Taste function recovery. Objectives The aim of the present systematic review was to assess the effects of palliative and curative interventions on Taste recovery in light of recent literature. Materials and methods In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, a search of the literature published up to June 2019 was conducted using MEDLINE via PubMed, EMBASE, and The US National Institutes of Health Trials Register (PROSPERO registration reference: CRD 42019139315). The methodological quality of the included trials was rated with the “Delphi list For Quality Assessment of Randomized Clinical Trials” and the Newcastle-Ottawa scale. Results From the 1842 titles first identified, 28 articles met the inclusion criteria. Interventions included zinc (aspartate, sulfate, gluconate, acetate, picolinate, and Polaprezinc®), esomeprazole, l -thyroxin, bethanechol, oral glutamine, delta-9-tetrahydrocannabinol, alpha-lipoic acid, Ginkgo biloba , artificial saliva, pilocarpine, local anesthesia, and improved oral hygiene. The quality of evidence ranged from poor to high. Conclusion Improving oral hygiene may promote Taste ability. Zinc may prevent and alleviate Taste Disorder in patients undergoing head and neck radiotherapy. Clinical relevance The systematic review provided evidence about the clinical efficacy of oral procedures, zinc supplementation, and palliative cares in dysgeusic patients. Further research is needed to find effective treatments with low adverse effects.
Masafumi Sakagami - One of the best experts on this subject based on the ideXlab platform.
-
S128 – Diagnosis and Treatment of 703 Patients with Taste Disorder
Otolaryngology–Head and Neck Surgery, 2020Co-Authors: Shinya Miuchi, Masanori Umemoto, Atsushi Negoro, Masafumi SakagamiAbstract:Objectives As life spans increase, the number of patients with Taste Disorder consulting in our Taste clinic has increased. This study prospectively examined patients’ history, causes of Taste Disorder, and treatment outcomes. Methods Subjects consisted of 703 patients with Taste Disorder who consulted our Taste clinic at the department of Otolaryngology, Hospital of Hyogo College of Medicine, between 1999 and 2007. There were 284 men and 419 women, and patient ages ranged from 12 years to 88 years with a mean age of 59.7 years. Electrogustometry (EGM) and filter paper disk method (FPD) were used to assess Taste function. We also asked each patient to indicate the severity of symptoms using a visual analog scale (VAS). Patients were treated mainly with zinc sulfate (ZnSO4 300 mg/day, or polaprezinc 150 mg/day), and in some cases with iron supplement, herbal medicine, and minor tranquilizers. Results Idiopathic Taste Disorder was the most common cause (271 cases, 38.5%), followed by drug-induced (131 cases, 18.6%), post-common cold (83 cases, 11.8%), psychogenic (73 cases, 10.4%), iron-deficiency (37 cases, 5.3%) and others. Deficiency of serum zinc (less than 70 ?g/dl) was found in 50–70% of cases. The recovery rate was 130/183 (71.0%) in idiopathic, 41/61 (67.2%) in post-common cold, and 24/29 (82.8%) in iron deficiency. The recovery period in drug-induced (39.7 weeks) was longer than that in other cases (20.4 weeks). Results of EGM and FPD were not always associated with the severity of symptoms. Conclusions Treatment with zinc supplement may be useful for Taste Disorder.
-
time course of changes in gustatory function test results and subjective symptoms and predictive factors for response in patients with Taste Disorder receiving 24 week zinc replacement treatment
Nippon Jibiinkoka Gakkai Kaiho, 2014Co-Authors: Masafumi Sakagami, Akira Inokuchi, Yuichi Kurono, Noriaki Takeda, Tsunemasa Aiba, Minoru IkedaAbstract:: In a Taste Disorder, an agreement between patients' complaints and gustatory function test results is not necessarily found both at the initial hospital visit and during the course of treatment; therefore, it is difficult to assess treatment responses and review treatment strategies based on the assessed treatment responses. The present study investigated the time course of changes in disc gustometry results and subjective symptom scores measured at 4-week intervals in 44 patients with a Taste Disorder who were considered eligible for zinc replacement treatment and who received polaprezinc at a dose of 150 mg/day (equivalent to a 34 mg/day dose of zinc) for up to 24 weeks. The study also examined the potential differences in treatment outcomes according to the predictive factors for response such as patient background and assessed disc gustometry results during the course of treatment. Results indicated that disc gustometry results and subjective symptom scores showed different time courses of changes. The response rate as measured by disc gustometry was 47.7% at week 12 of treatment, and showed a subsequent slow increase to 56.8% at week 24. On the other hand, subjective symptom scores showed a time-proportional improvement up to week 24. Among the patients included in the present study, a clear difference was found according to the presence or absence of an improving trend as determined by disc gustometry at week 12 of treatment, although there were no differences in ultimate treatment responses, including categories of Taste Disorder, according to patient background. Patients showing a trend toward improvement had significantly better treatment responses in terms of both ultimate response rates and subjective symptom scores, whereas patients showing no trend toward improvement were less likely to respond to the subsequent 12-week continued treatment.
-
Clinical analysis of 1059 patients with Taste Disorders
Nippon Jibiinkoka Gakkai Kaiho, 2013Co-Authors: Akiko Sakaguchi, Atsushi Negoro, Masanori Umemoto, Emi Maeda, Masafumi SakagamiAbstract:: Taste Disorders are caused by several factors, and there have been few reports concerning the clinical course of Taste Disorders. In this study, patients with Taste Disorders were classified into 10 groups according to causes, and they were retrospectively studied in terms of therapeutic effects. In total, 1059 patients (412 men and 647 women, mean age: 60.0 years) who complained of Taste Disorders were reviewed in our clinic. The patients were asked detailed questions about their history of symptoms, and their emotional status was assessed using a self-rating depression scale. In all subjects, Taste functions were measured by electrogustometry (EGM) and filter paper disks (FPD). The grades of their symptoms were assessed with a visual analogue scale (VAS). In addition, the levels of serum iron, copper, and zinc were examined. The patients were treated with zinc sulfate, polaprezinc, iron preparation, herbal medicine, and minor tranquilizers according to the factors causing the Taste Disorders. The most frequent cause was idiopathic Taste Disorder (192 cases, 18.2%), the second was psychogenic (186 cases, 17.6%), and the third was drug-induced (179 cases, 16.9%). The recovery rate of the symptoms was 64/92 (70.2%) in post-common cold, 31/35 (88.6%) in iron deficiency, and 85/116 (73.3%) in zinc deficiency. In these groups, the rates of recoveries were better than in the other groups. The recovery period in drug-induced Taste Disorders was approximately twice as long as the recovery period in the other groups. In the patients who were able to start treatment within 6 months from the onset of Taste Disorder, the recovery rate was significantly higher and the therapeutic period was significantly shorter than in those who had the Disorders for more than 6 months (p
-
the effect of zinc agent in 219 patients with zinc deficiency inductive idiopathic Taste Disorder a placebo controlled randomized study
Nippon Jibiinkoka Gakkai Kaiho, 2013Co-Authors: Minoru Ikeda, Akira Inokuchi, Yuichi Kurono, Noriaki Takeda, Tsunemasa Aiba, Yasuyuki Nomura, Masafumi SakagamiAbstract:: Diagnosis and treatment of Taste Disorders are challenging because the Disorder can only be determined by the awareness of the patient. Hence, these Disorders still require comprehensive evidence. We conducted a randomized, placebo-controlled double-blind study to investigate the effect of polaprezinc, a zinc-containing agent, in 219 patients with either zinc deficiency-inductive or an idiopathic Taste, Disorder. As a result, the zinc-treated arm experienced a statistically significant improvement against the placebo-treated arm in the perceptible threshold scores of the filter-paper disk method 8 weeks after the administration of the investigational drug. Moreover, the effect lasted for 4 weeks after discontinuation of the drug. However, the effective ratios based on the initial criteria were 55.6% in the treatment group and 43.2% in the placebo, where no statistical significance was recorded. Sex and degree of depression could be two of the potential factors to explain this discrepancy. Furthermore, the effect was not significant among male patients and patients with a high depression score based on the Self-rating Depression Scale (SDS) test. These results indicate that determining the symptom among such patients remains undisclosed. Whereas, in approximately 77%, or 168 patients with "normal" SDS scores and with completely impaired Taste qualities, the ratio of effective cases reached 60.9% in the zinc-treated group, the ratio of the placebo-treated group reached 39.5%, resulting in a statistical significance. This may be partly because of a problem in the adaption of male subjects to the gustatory analyses, especially to the identification of saltiness and sourness. Care must also be taken regarding the depressive state of patients when diagnosing and treating Taste Disorders. Taste Disorders caused by depression may not be cured by zinc supplementation due in part to the fact that the symptom is based on a mental issue, and due in part to the conservative responding bias generated by the depression itself, which may inhibit accurate and precise diagnosis of the Disorder. In conclusion, administration of a zinc agent is effective for patients with Taste Disorders, provided selection of appropriate patients is performed, and that proper examination and evaluation are conducted. The present study also indicated that examining depressiveness based on the SDS scores and investigating disturbance of each Taste quality using the filter-paper disk method are recommended for the diagnosis and determination of the treatment effect of a Taste Disorder.
-
Taste Disorder after middle ear surgery
2009Co-Authors: Masafumi SakagamiAbstract:(1) Taste Disorder occurs more frequently with preservation of the chorda tympani nerve (CTN) than with section of CTN. (2) With preservation of CTN, the recovery rate of CTN function is higher in younger patients than in middle-aged or older patients. (3) Taste Disorder easily occurs and persists in patients with non-inflammatory disease such as otosclerosis. (4) With unilateral section of CTN, about 50% of patients complain of Taste Disorder, however Taste Disorder will cease within one year in most cases. (5) Recovery of threshold of electrogustometry is not related to recovery of symptoms, and it is delayed in most cases. (6) Even with bilateral section of CTN, patients do not complain of difficulty in tasting food within two years. (7) Elderly patients complain of Taste Disorder less frequently because Taste naturally deteriorates with aging. (8) Because CTN has the ability to regenerate, it is desirable to preserve CTN during surgery or to anastomose the nerve ends if CTN is unavoidably cut. (9) Trigeminal sensations such as tongue numbness, tingling, and metallic Taste may also develop after surgery, however the mechanism remains unclear. The chorda tympani nerve (CTN) controls Taste in the anterior two-thirds of the tongue on each side; it runs close to the annulus of the tympanic membrane, crossing the tympanic cavity between the incus and malleus. The CTN is initially encountered at this location when elevating the annulus and it is frequently damaged by traction, stretching and cutting during surgical proce
